Department of Radiology, Mayo Clinic, Rochester, Minnesota; Nuffield Department of Primary Care Health Sciences and Department for Continuing Education (Evidence-Based Healthcare Program), Oxford University, Oxford, United Kingdom.
Nested Knowledge, Saint Paul, Minnesota.
J Vasc Interv Radiol. 2023 Nov;34(11):1946-1954.e5. doi: 10.1016/j.jvir.2023.05.039. Epub 2023 Jul 17.
To evaluate the safety of >8-F access closures using 8-F Angio-Seal.
An electronic search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines using Web of Science, Embase, Scopus, and PubMed databases from inception until January 17, 2022. Actionable and nonactionable bleeding events were defined in conjugation with the Bleeding Academic Research Consortium definition. Prevalence rates with corresponding 95% CIs were calculated using R software version 4.2.2. Eight articles, with 422 patients, were included in the analysis.
The overall groin adverse event rate was 5.92% (95% CI, 3.01-11.34). The most commonly reported adverse events were any bleeding (5.74%; 95% CI, 3.23-10.00) (nonactionable bleeding, 0.96% [95% CI, 0.10-8.30]; actionable bleeding, 2.30% [95% CI, 0.89-5.84]), pseudoaneurysm (1.18%; 95% CI, 0.49-2.81), and groin hematoma (1.28%; 95% CI, 0.23-6.79). The least commonly reported adverse events were device failure and vessel occlusion/stenosis, with rates 0.29% (95% CI, 0.01-7.41) and 0.45% (95% CI, 0.02-7.74), respectively. No studies recorded events regarding the following adverse events: mortality, infection, deep venous thrombosis, and retroperitoneal hematoma. Moreover, the results showed significant differences, based on the sheath size used, in actionable bleeding (P = .04) and the rate of need for surgical repair (P < .01).
Common femoral artery access of >8-F can be effectively closed with the Angio-Seal with comparable outcomes to those of <8 F; however, larger access approaching 14 F is associated with a significant increase in morbidity. Further safety is needed, especially for the larger access sizes.
评估使用 8-F 血管密封器对>8-F 入路进行封堵的安全性。
根据 2020 年系统评价和荟萃分析的首选报告项目指南,使用 Web of Science、Embase、Scopus 和 PubMed 数据库,从创建到 2022 年 1 月 17 日进行电子检索。与 Bleeding Academic Research Consortium 定义相结合,定义了有症状和无症状出血事件。使用 R 软件版本 4.2.2 计算患病率及其相应的 95%置信区间。共有 8 篇文章,422 例患者纳入分析。
总的腹股沟不良事件发生率为 5.92%(95% CI,3.01-11.34)。最常报告的不良事件为任何出血(5.74%;95% CI,3.23-10.00)(无症状出血 0.96%[95% CI,0.10-8.30];有症状出血 2.30%[95% CI,0.89-5.84])、假性动脉瘤(1.18%;95% CI,0.49-2.81)和腹股沟血肿(1.28%;95% CI,0.23-6.79)。报道最少的不良事件为器械故障和血管闭塞/狭窄,发生率分别为 0.29%(95% CI,0.01-7.41)和 0.45%(95% CI,0.02-7.74)。没有研究记录与以下不良事件相关的事件:死亡率、感染、深静脉血栓形成和腹膜后血肿。此外,根据使用的鞘管大小,有症状出血(P=.04)和需要手术修复的比率(P<.01)存在显著差异。
8-F 股动脉入路可有效用血管密封器封堵,结果与<8-F 相似;然而,接近 14-F 的较大入路与发病率显著增加相关。需要进一步的安全性评估,特别是对于较大的入路尺寸。